Association of SARS susceptibility with single nucleic acid polymorphisms of OAS1 and MxA genes: a case-control study

Jing He, Dan Feng, Sake J de Vlas, Hongwei Wang, Arnaud Fontanet, Panhe Zhang, Sabine Plancoulaine, Fang Tang, Lin Zhan, Hong Yang, Tianbao Wang, Jan H Richardus, J Dik F Habbema, Wuchun Cao, Jing He, Dan Feng, Sake J de Vlas, Hongwei Wang, Arnaud Fontanet, Panhe Zhang, Sabine Plancoulaine, Fang Tang, Lin Zhan, Hong Yang, Tianbao Wang, Jan H Richardus, J Dik F Habbema, Wuchun Cao

Abstract

Background: Host genetic factors may play a role in susceptibility and resistance to SARS associated coronavirus (SARS-CoV) infection. The study was carried out to investigate the association between the genetic polymorphisms of 2',5'-oligoadenylate synthetase 1 (OAS1) gene as well as myxovirus resistance 1 (MxA) gene and susceptibility to SARS in Chinese Han population.

Methods: A hospital-based case-control study was conducted. A collective of 66 SARS cases and 64 close contact uninfected controls were enrolled in this study. End point real time polymerase chain reaction (PCR) and PCR-based Restriction Fragment Length Polymorphism (RFLP) analysis were used to detect the single nucleic polymorphisms (SNPs) in OAS1 and MxA genes. Information on other factors associated with SARS infection was collected using a pre-tested questionnaire. Univariate and multivariate logistic analyses were conducted.

Results: One polymorphism in the 3'-untranslated region (3'-UTR) of the OAS1 gene was associated with SARS infection. Compared to AA genotype, AG and GG genotypes were found associated with a protective effect on SARS infection with ORs (95% CI) of 0.42 (0.20-0.89) and 0.30 (0.09-0.97), respectively. Also, a GT genotype at position 88 in the MxA gene promoter was associated with increased susceptibility to SARS infection compared to a GG genotype (OR = 3.06, 95% CI: 1.25-7.50). The associations of AG genotype in OAS1 and GT genotype in MxA remained significant in multivariate analyses after adjusting for SARS protective measures (OR = 0.38, 95% CI: 0.14-0.98 and OR = 3.22, 95% CI: 1.13-9.18, respectively).

Conclusion: SNPs in the OAS1 3'-UTR and MxA promoter region appear associated with host susceptibility to SARS in Chinese Han population.

References

    1. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Penaranda S, Bankamp B, Maher K, Chen MH, Tong S, Tamin A, Lowe L, Frace M, DeRisi JL, Chen Q, Wang D, Erdman DD, Peret TC, Burns C, Ksiazek TG, Rollin PE, Sanchez A, Liffick S, Holloway B, Limor J, McCaustland K, Olsen-Rasmussen M, Fouchier R, Gunther S, Osterhaus AD, Drosten C, Pallansch MA, Anderson LJ, Bellini WJ. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science. 2003;300:1394–1399. doi: 10.1126/science.1085952.
    1. World Health Organization Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July
    1. Ashraf H. WHO declares Beijing to be free of SARS. Lancet. 2003;361:2212. doi: 10.1016/S0140-6736(03)13790-7.
    1. Lee A. Host and environment are key factors. J Epidemiol Community Health. 2003;57:770. doi: 10.1136/jech.57.10.770.
    1. Ng MH, Lau KM, Li L, Cheng SH, Chan WY, Hui PK, Zee B, Leung CB, Sung JJ. Association of human-leukocyte-antigen class I (B*0703) and class II (DRB1*0301) genotypes with susceptibility and resistance to the development of severe acute respiratory syndrome. J Infect Dis. 2004;190:515–518. doi: 10.1086/421523.
    1. Lin M, Tseng HK, Trejaut JA, Lee HL, Loo JH, Chu CC, Chen PJ, Su YW, Lim KH, Tsai ZU, Lin RY, Lin RS, Huang CH. Association of HLA class I with severe acute respiratory syndrome coronavirus infection. BMC Med Genet. 2003;4:9. doi: 10.1186/1471-2350-4-9.
    1. Itoyama S, Keicho N, Quy T, Phi NC, Long HT, Ha le D, Ban VV, Ohashi J, Hijikata M, Matsushita I, Kawana A, Yanai H, Kirikae T, Kuratsuji T, Sasazuki T. ACE1 polymorphism and progression of SARS. Biochem Biophys Res Commun. 2004;323:1124–1129. doi: 10.1016/j.bbrc.2004.08.208.
    1. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Treatment of SARS with human interferons. Lancet. 2003;362:293–294. doi: 10.1016/S0140-6736(03)13973-6.
    1. Enserink M. SARS treatment: Interferon shows promise in monkeys. Science. 2004;303:1273–1275. doi: 10.1126/science.303.5662.1273a.
    1. Stroher U, DiCaro A, Li Y, Strong JE, Aoki F, Plummer F, Jones SM, Feldmann H. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-alpha. J Infect Dis. 2004;189:1164–1167. doi: 10.1086/382597.
    1. Rebouillat D, Hovanessian AG. The human 2',5'-oligoadenylate synthetase family: interferon-induced proteins with unique enzymatic properties. J Interferon Cytokine Res. 1999;19:295–308. doi: 10.1089/107999099313992.
    1. Schwemmle M, Weining KC, Richter MF, Schumacher B, Staeheli P. Vesicular stomatitis virus transcription inhibited by purified MxA protein. Virology. 1995;206:545–554. doi: 10.1016/S0042-6822(95)80071-9.
    1. Landis H, Simon-Jodicke A, Kloti A, Di Paolo C, Schnorr JJ, Schneider-Schaulies S, Hefti HP, Pavlovic J. Human MxA protein confers resistance to Semliki Forest virus and inhibits the amplification of a Semliki Forest virus-based replicon in the absence of viral structural proteins. J Virol. 1998;72:1516–1522.
    1. Hefti HP, Frese M, Landis H, Di Paolo C, Aguzzi A, Haller O, Pavlovic J. Human MxA protein protects mice lacking a functional alpha/beta interferon system against La crosse virus and other lethal viral infections. J Virol. 1999;73:6984–6991.
    1. Suzuki F, Arase Y, Suzuki Y, Tsubota A, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Matsuda M, Takagi K, Satoh J, Kumada H. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J Viral Hepat. 2004;11:271–276. doi: 10.1111/j.1365-2893.2004.00509.x.
    1. Knapp S, Yee LJ, Frodsham AJ, Hennig BJ, Hellier S, Zhang L, Wright M, Chiaramonte M, Graves M, Thomas HC, Hill AV, Thursz MR. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun. 2003;4:411–419. doi: 10.1038/sj.gene.6363984.
    1. Hamano E, Hijikata M, Itoyama S, Quy T, Phi NC, Long HT, Ha le D, Ban VV, Matsushita I, Yanai H, Kirikae F, Kirikae T, Kuratsuji T, Sasazuki T, Keicho N. Polymorphisms of interferon-inducible genes OAS-1 and MxA associated with SARS in the Vietnamese population. Biochem Biophys Res Commun. 2005;329:1234–1239. doi: 10.1016/j.bbrc.2005.02.101.
    1. Ma HJ, Wang HW, Fang LQ, Jiang JF, Wei MT, Liu W, Zhao QM, Ma J, Cao WC. A case-control study on the risk factor s of sever e acute respiratory syndromes among health care workers. Chin J Epidemiol. 2004;25:741–744.
    1. Pang XH, Liu DL, Gong XH, Xu FJ, Liu ZJ, Zhang Z, Wang XH, Jiao XR, Su LY, Gao GH. Study on the risk factors related to severe acute respiratory syndrome among close contactors in Beijing. Chin J Epidemiol. 2004;25:674–676.
    1. Wang M, Du L, Zhou DH, Di B, Liu YF, Qin PZ, Wu XW, Chen XS, Qiu JC, Li ZR. Study on the epidemiology and measures for control on severe acute respiratory syndrome in Guangzhou city. Chin J Epidemiol. 2003;24:353–3757.
    1. Mashimo T, Lucas M, Simon-Chazottes D, Frenkiel MP, Montagutelli X, Ceccaldi PE, Deubel V, Guenet JL, Despres P. A nonsense mutation in the gene encoding 2'-5'-oligoadenylate synthetase/L1 isoform is associated with West Nile virus susceptibility in laboratory mice. Proc Natl Acad Sci U S A. 2002;99:11311–11316. doi: 10.1073/pnas.172195399.
    1. Lucas M, Mashimo T, Frenkiel MP, Simon-Chazottes D, Montagutelli X, Ceccaldi PE, Guenet JL, Despres P. Infection of mouse neurones by West Nile virus is modulated by the interferon-inducible 2'-5' oligoadenylate synthetase 1b protein. Immunol Cell Biol. 2003;81:230–236. doi: 10.1046/j.1440-1711.2003.01166.x.
    1. Benech P, Mory Y, Revel M, Chebath J. Structure of two forms of the interferon-induced (2'-5') oligo A synthetase of human cells based on cDNAs and gene sequences. EMBO J. 1985;4:2249–2256.
    1. Aissouni Y, Perez C, Calmels B, Benech PD. The cleavage/polyadenylation activity tr igger ed by a U-rich motif sequence is differently required depending on the poly(A) site location at either the fir st or last 3'-terminal exon of the 2'-5' oligo(A) synthetase gene. J Biol Chem. 2002;277:35808–35814. doi: 10.1074/jbc.M200540200.
    1. Spiegel M, Pichlmair A, Muhlberger E, Haller O, Weber F. The antiviral effect of interferon-beta against SARS-coronavir us is not mediated by MxA protein. J Clin Virol. 2004;30:211–213.
    1. Scagnolari C, Vicenzi E, Bellomi F, Stillitano MG, Pinna D, Poli G, Clementi M, Dianzani F, Antonelli G. Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antivir Ther. 2004;9:1003–1011.
    1. Torisu H, Kusuhara K, Kira R, Bassuny WM, Sakai Y, Sanefuji M, Takemoto M, Hara T. Functional MxA promoter polymorphism associated with subacute sclerosing panencephalitis. Neurology. 2004;62:457–460.
    1. Hijikata M, Mishiro S, Miyamoto C, Furuichi Y, Hashimoto M, Ohta Y. Genetic polymorphism of the MxA gene promoter and interferon responsiveness of hepatitis C patients: revisited by analyzing two SNP sites (-123 and -88) in vivo and in vitro. Intervirology. 2001;44:379–382. doi: 10.1159/000050075.
    1. Fernandez-Arcas N, Blanco A, Gaitan MJ, Nyqvist M, Alonso A, Reyes-Engel A. Differential transcriptional expresion of the polymorphic myxovirus resistance protein A in response to interferon-alpha treatment. Pharmacogenetics. 2004;14:189–193. doi: 10.1097/00008571-200403000-00007.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa